Skip to content
ClinCalc Pro
Menu
Topical otic steroid + antibiotic combination Pregnancy: Not recommended in pregnancy or lactation. Section 4.6 verbatim: 'There is little information to demonstrate the possible effect of topically applied neomycin in pregnancy and lactation. However, neomycin present in maternal blood can cross the placenta and may give rise to a theoretical risk of foetal toxicity thus use of Otosporin Ear Drops is not recommended in pregnancy or lactation.'

Hydrocortisone with neomycin and polymyxin B

Brand names: Otosporin

A compound topical preparation combining the corticosteroid hydrocortisone with the antibiotics neomycin and polymyxin B sulfate, used for infected inflammatory conditions of the ear or eye.

Adult dose

Dose: Topical treatment of the ear: three drops instilled into the affected ear. Alternatively, a gauze wick may be introduced into the external auditory canal and kept saturated with the solution; the wick may be left in place for 24 to 48 hours. Cleanse and dry the external auditory meatus and canal as appropriate before instillation.
Route: Topical (otic) - for topical administration into the ear ONLY. Not suitable for use in the eye. If ear drops are accidentally introduced into the eye, the eye should be rinsed thoroughly with water.
Frequency: Three or four times daily. Treatment should not be continued for more than 7 days without medical supervision.
Max: 3 drops per instillation, four times daily into the affected ear; treatment not to be continued for more than 7 days without medical supervision
UK SPC (Otosporin Ear Drops) section 4.2, verbatim: 'Otosporin ear drops are for topical administration into the ear only. Adults Following cleansing and drying of the external auditory meatus and canal as appropriate, three drops should be instilled into the affected ear three or four times daily. Alternatively, a gauze wick may be introduced into the external auditory canal and kept saturated with the solution; the wick may be left in place for 24 to 48 hours. Treatment should not be continued for more than 7 days without medical supervision. Soap should not be used for cleansing of the external auditory meatus and canal as it may inactivate the antibiotics.' SOAP: do not use soap to cleanse the meatus and canal - it may inactivate the antibiotics. ELDERLY: 'As for adults. Caution should be exercised in cases where a decrease in renal function exists and significant systemic absorption of neomycin sulphate may occur.' RENAL IMPAIRMENT: 'Dosage should be reduced in patients with reduced renal function' - the SPC gives no numeric reduced regimen, so none is stated here. SEVEN-DAY LIMIT: section 4.4 adds that treatment with topical steroid/antibiotic combinations should not be continued for more than seven days in the absence of any clinical improvement, since prolonged use may lead to occult extension of infection due to the masking effect of the steroid, to skin sensitisation and to emergence of resistant organisms. ADMINISTRATION ERRORS: accidental maladministration, prescription and dispensing errors have been reported - particular care should be taken to ensure the correct formulation has been provided and administered. SCOPE CAVEAT: sections 4.2, 4.3, 4.6 and 4.8 were captured in full; section 4.4 was cut at the source-fetch limit part-way through the aminoglycoside/mitochondrial-mutation paragraph, so the warnings list below is not complete - consult the full SPC.

Paediatric dose

Route: Topical (otic) - three drops instilled into the affected ear
Frequency: Three or four times daily (children 3 years and over, same as adults)
Max: 3 drops per instillation, four times daily; not more than 7 days without medical supervision
NOT WEIGHT-BASED - this is a topical otic drop, so dosePerKg is deliberately left null and the weight calculator is unset. Section 4.2 verbatim: 'Children Otosporin Ear Drops are suitable for use in children ( 3 years and over) at the same dose as adults. A possibility of increased absorption exists in very young children, thus Otosporin Ear Drops are not recommended in neonates and infants (<3 years).' Section 4.3 repeats this as a contraindication and explains why: 'In neonates and infants, absorption by immature skin may be enhanced and renal function may be immature.' Section 4.4 adds that development of adverse systemic effects from the hydrocortisone component is considered unlikely, 'although the recommended dosage should not be exceeded, particularly in infants.' Verify against a children's formulary before use.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Known or suspected perforation of the tympanic membrane
  • Allergic hypersensitivity to any of the components of the preparation, or to cross-sensitising substances such as framycetin, kanamycin, gentamicin and other related antibiotics
  • Presence of untreated viral, fungal and tubercular infections
  • Not recommended in neonates and infants (up to 3 years) - a possibility of increased absorption exists in very young children; absorption by immature skin may be enhanced and renal function may be immature
  • Use in large quantities, or on large areas, for prolonged periods is not recommended in circumstances where significant systemic absorption may occur, because of the known ototoxic and nephrotoxic potential of neomycin sulphate
  • Not recommended in pregnancy or lactation (section 4.6)

Side effects

  • Allergic hypersensitivity to neomycin following topical use - may manifest as an eczematous exacerbation with reddening, scaling, swelling and itching, or as failure of the lesion to heal. Incidence in the general population is low but is increased in venous stasis eczema and ulceration and in chronic otitis externa
  • Allergic hypersensitivity reactions to topical polymyxin B sulphate and hydrocortisone are rare
  • Stinging and burning - occasionally reported when the drops gained access to the middle ear
  • Rare (post-marketing): application site hypersensitivity; headache; application site reaction including pain, irritation, oedema, burning sensation and rash
  • Rare (post-marketing), skin and subcutaneous tissue: local exfoliative dermatitis, skin atrophy, telangiectasia, striae, exacerbation of underlying skin conditions including eczema
  • Systemic risks after significant absorption (section 4.4): irreversible ototoxicity from neomycin; nephrotoxic potential of neomycin and polymyxin B sulphate; neurotoxic potential of polymyxin B sulphate; potential suppression of the pituitary-adrenal axis from the corticosteroid

Monitoring

  • Review at 7 days - treatment should not be continued beyond 7 days without medical supervision, nor beyond seven days in the absence of clinical improvement
  • Renal function - caution and dose reduction where renal function is reduced, because plasma clearance of neomycin is decreased and prolonged unsupervised use may lead to irreversible partial or total deafness, especially in the elderly and in patients with impaired renal function
  • Watch for delayed hypersensitivity to corticosteroids, skin sensitisation and emergence of resistant organisms on prolonged use
  • Discontinue immediately and investigate further if prolonged or significant diarrhoea or abdominal cramps occur (pseudomembranous colitis has been reported with antibiotics, although this is unlikely with topical application)
  • Avoid use in the immediate pre- and post-operative period - neomycin may rarely cause neuromuscular block and potentiates skeletal muscle relaxants, which may cause respiratory depression and arrest
  • Increased risk of ototoxicity with aminoglycosides in patients with mitochondrial mutations, particularly m.1555A>G, sometimes with a maternal history of deafness and/or mitochondrial mutation

Clinical monograph

How it works

Neomycin (an aminoglycoside) and polymyxin B provide complementary antibacterial cover against Gram-positive and Gram-negative organisms, while hydrocortisone reduces local inflammation.

Prescribing in practice

  • Avoid use in the ear when the tympanic membrane is perforated, as topical neomycin (an aminoglycoside) carries a risk of ototoxicity in the middle ear.
  • Neomycin is a common contact sensitiser, so discontinue if local hypersensitivity develops.
  • Reserve for short courses and reassess if there is no improvement to limit sensitisation and superinfection.

Monitoring

Monitor for clinical improvement and for any local hypersensitivity or, with ear use, hearing disturbance during treatment.

Counselling the patient

  • Use only at the affected site and complete the short course as directed.
  • Stop and seek advice if you develop a rash, itching or, with ear use, hearing changes or dizziness.
  • Tell the clinician if your eardrum may be perforated before using drops in the ear.

Evidence & guidelines

Combined antibiotic-corticosteroid topical preparations are established for infected otitis externa and external eye infection, used cautiously per UK guidance.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.